Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,877	$ 5,864
Marketable securities	32,704	42,675
Prepaid expenses and other current assets	1,809	2,308
Total current assets	41,390	50,847
Property and equipment, net	5,905	6,105
Operating lease right-of-use asset	5,971	718
Other assets	246	246
Total assets	53,512	57,916
Current liabilities:
Accounts payable	806	648
Accrued expenses and other current liabilities	2,761	1,726
Current portion of long-term debt	8,586	4,897
Current portion of operating lease liability	1,222	718
Total current liabilities	13,375	7,989
Long-term debt, less current portion	20,853	24,484
Operating lease liability, less current portion	4,749	0
Total liabilities	38,977	32,473
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	87,776	85,762
Accumulated other comprehensive loss	(11)	(12)
Accumulated deficit	(80,372)	(72,889)
Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc.	7,398	12,866
Non-controlling interest	7,137	12,577
Total stockholders' equity	14,535	25,443
Total liabilities and stockholders' equity	53,512	57,916
Common Class A [Member]
Stockholders' equity:
Common stock, value	3	3
Common Class B [Member]
Stockholders' equity:
Common stock, value	2	2
Common Class C [Member]
Stockholders' equity:
Common stock, value	$ 0	$ 0